Commit Biologics: $16m Seed for Cancer & Autoimmune


Version 1: Commit Biologics, a company specializing in utilizing the complement system to combat cancer and autoimmune diseases, has emerged from stealth mode today with €16m in seed funding from Bioqube Ventures and Novo Holdings.

The company aims to expedite the advancement of its Bispecific Complement Engaging platform, which employs single domain antibodies to target the complement protein C1q and activate the complement system - a powerful component of the innate immune system. BiCE™ is a versatile system that equips antibodies to guide the complement system in a precise manner, enabling the selective elimination of cancer cells or immune cells involved in autoimmune disorders.

Originating from Aarhus University in Denmark, Commit has established itself as a leading entity in complement system biology globally over the past thirty years. Initially nurtured and backed by the BioInnovation Institute in Denmark, the company is now ready to make a significant impact in the field.

Comments

Popular posts from this blog

Aon Unveils $350M Program for Ukraine Recovery

TECNO CAMON 20 Premier 5G and PHANTOM V Flip 5G Secure German Design Awards 2024

Lion Energy Unveils 10W Solar Panel for Portable Power